Redox double-switch cancer theranostics through Pt(iv) functionalised manganese dioxide nanostructures

Beatriz Brito, Maria Rosaria Ruggiero, Thomas W. Price, Milene da Costa Silva, Núria Genicio, Annah J. Wilson, Olga Tyurina, Veronika Rosecker, Thomas R. Eykyn, Manuel Bañobre-López, Graeme J. Stasiuk, Juan Gallo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Manganese dioxide (MnO2)-based nanostructures have emerged as promising tumour microenvironment (TME) responsive platforms. Herein, we used a one-pot reaction to prepare MnO2 nanostructures with Pt(iv) prodrugs as redox- (and thus TME-) responsive theranostics for cancer therapy, in which the Pt(iv) complexes act as prodrugs of cisplatin (Pt(ii)), a clinical chemotherapeutic drug. The cytotoxicity of these MnO2-Pt(iv) probes was evaluated in two and three dimensional (2D and 3D) A549 cell models and found to be as effective as active drug cisplatin in 3D models. Moreover, MnO2-Pt(iv) nanoparticles exhibited strong off/ON magnetic resonance (MR) contrast in response to reducing agents, with the longitudinal relaxivity (r1) increasing 136-fold upon treatment with ascorbic acid. This off/ON MR switch was also observed in (2D and 3D) cells in vitro. In vivo MRI experiments revealed that the nanostructures induce a strong and long-lasting T1 signal enhancement upon intratumoral injection in A549 tumour-bearing mice. These results show the potential of MnO2-Pt(iv) NPs as redox responsive MR theranostics for cancer therapy.

Original languageEnglish
Pages (from-to)10763-10775
Number of pages13
JournalNanoscale
Volume15
Issue number25
DOIs
Publication statusPublished - 13 Jun 2023

Fingerprint

Dive into the research topics of 'Redox double-switch cancer theranostics through Pt(iv) functionalised manganese dioxide nanostructures'. Together they form a unique fingerprint.

Cite this